Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on October 30th, 2015 by Thibault GeouiChemistry
Antipsychotics have complex pharmacological profiles and adverse events are common with long-term use. New or optimized drugs with better safety profiles are desirable. The best way to get information on a new compound that has potential as an antipsychotic is to use in silico profiling to compare it to existing drugs, as described in this new paper.
Speeding up Science: How We Can Stop the Decline of Drug Production as Scientific Information Increases
Posted on October 28th, 2015 by Thibault GeouiChemistry
Every 9 years, scientific output is doubling and more information is being made available to the world’s top scientists. Contrary to common sense and public opinion, for every 1 billion invested in drug development, the number of drugs approved has been halved every 9 years, and approximately 70% of drugs sold in the US today are generics. (more…)
Posted on October 27th, 2015 by Thibault GeouiChemistry
Information is useful only when it can be found. Taxonomies offer obvious organizational benefits, but their impact on database usability is far-reaching.
Read an excerpt from the Elsevier whitepaper, The Means to Use Information, to discover how to maximize taxonomies and learn how to utilize intelligent and connected taxonomies to take your insightful research to the next level. (more…)
Posted on October 27th, 2015 by Neal KatzPharmacovigilance
Pharmacovigilance is defined as “the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems.” Under that umbrella, government agencies in the United States, the European Union and other parts of the world have developed diverse and increasingly complex regulatory requirements. (more…)
Posted on October 27th, 2015 by Julio dos AnjosPharmacovigilance
Although, quite a lot of existing flows have to change and new ones have to be implemented, there are, also, quite a lot of benefits, most of them for EMA, and some, not so obvious, for the MAH’s. Of these last ones, many are found by looking at the information, now made available by EMA, as an information professional in a pharmacovigilance context, as well as a pharmacovigilance analyst in an information rich environment.
Posted on October 23rd, 2015 by Thibault GeouiChemistry
Read an excerpt from the Elsevier whitepaper, Big Data, Wider Mindset to discover how systems biology and systems chemistry enable a holistic view of a biological system that is more than it’s sum of molecular components.
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.